Dr Ana-Mishel (AM) Spiroski is Vice President Biosciences, leading our Biosciences business unit across Biology and Toxicology. Bringing over 20 years of experience leading preclinical and translational Drug Discovery programs, Ana-Mishel focuses on accelerating end to end drug discovery, strengthening translational integration to drive high quality outcomes for our clients and partners.

Ana-Mishel joined us from Evotec where she established the Cardiovascular Therapeutic Area, leading multi-site teams to enable expansion and platform innovation across modalities for this and the Age-related Diseases Therapeutic Area. She has experience across a range of Disease Areas including Immune-mediated Diseases, Fibrotic, Metabolic and Rare Diseases. Ana-Mishel has led Drug Discovery teams across a broad range of modalities, with a significant focus on NextGen therapies.